Will paxalisib be successful in a host of high-profile Clinical Trials - this THREE day , scientific conference attended by dozens of research hospitals from around the world (mostly Europe though) ........they are pretty much wasting their time in this overall drug class, if indeed paxalisib can't make it....eg GBM.
Point is - this giant US$25 b company Kazia Therapeutics - has seemingly the premier PI3K drug in the world - the subject of which is this 3 day conference....... attended by a 100 of the leading cancer specialists from Europe and elsewhere. A fair enough and reasonable situation - except Kazia is not worth $25 billion - try $25 million. Pathetic.
The PI3K-AKT-mTOR-PTEN pathway: a new era in basic research and clinical translation
13-15 September 2023
Gran Hotel Rey Don Jaime, Castelldefels, Barcelona, Spain
Abstract & early booking deadlines: 13 July 2023.
This meeting will cover the broader PI3K pathway, including basic research in signalling and biology, the generation of improved pharmacological pathway modulators, and their use in cancer, immunity and rare diseases.
A better understanding of the clinical observations using PI3K pathway inhibitors – alongside progress in the pharmacological targeting of these enzymes, such as mutant-selective inhibitors, effective AKT inhibitors, and PI3K activators – is heralding a new phase of research and clinical development. Basic science investigations also continue to provide new insight into the pathway and the clinical observations, opening new opportunities for drug re-positioning. Together, these developments have created renewed interest in the field, which we are aiming to capture with this meeting. Programme Coordinators:
Mariona Graupera
Sigrid Skånland
Klaus Okkenhaug
Bart Vanhaesebroeck
Topics include:
Class I/II/III PI3K signalling and biology
AKT – mTOR signalling and biology
Structural insights into PI3K regulation
New pharmacological developments: PIK3CA-mutant selective inhibitors, PI3K activators
